Ascletis Pharma's (HKG:1672) attributed losses in 2024 widened year on year to 300.9 million yuan or 0.3005 yuan per share from 144.7 million yuan or 0.1347 yuan per share, according to a Hong Kong Stock Exchange disclosure on Wednesday.
The biotechnology company's revenue plummeted to 1.3 million yuan from 56.6 million yuan a year earlier.
The company's shares closed 10% lower.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。